AURA · Aura Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $90.30M | $73.30M | $65.23M | $42.24M | $18.04M |
| SG&A | $22.49M | $22.81M | $19.76M | $18.06M | $4.16M |
| Total Operating Expenses | $112.79M | $96.12M | $84.99M | $60.30M | $22.21M |
| D&A | $1.13M | $1.22M | $1.29M | $1.18M | $831.0K |
| Operating Income | ($112.79M) | ($96.12M) | ($84.99M) | ($60.30M) | ($22.21M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $108.0K | $112.0K | $137.0K | $0 | $0 |
| Net Income | ($106.19M) | ($86.92M) | ($76.41M) | ($58.76M) | ($22.21M) |
| EPS - Basic | ($1.76) | ($1.75) | ($1.93) | ($8.95) | - |
| EPS - Diluted | ($1.76) | ($1.75) | ($1.93) | ($8.95) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $59.52M | $31.69M | $41.06M | $121.58M | $149.06M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $1.55M | $2.30M | $1.79M | $2.92M | $2.40M |
| Current Assets | $149.74M | $160.62M | $231.79M | $196.70M | $153.70M |
| Total Assets | $169.43M | $182.50M | $255.07M | $223.94M | $160.03M |
| Current Liabilities | $18.38M | $14.91M | $12.36M | $10.46M | $7.27M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $32.52M | $30.53M | $29.23M | $28.35M | $7.71M |
| Stockholders' Equity | $136.91M | $151.97M | $225.85M | $195.58M | $152.31M |
| Retained Earnings | ($480.42M) | ($374.23M) | ($287.31M) | ($210.90M) | ($152.14M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($84.74M) | ($79.81M) | ($63.85M) | ($54.60M) | ($24.32M) |
| Investing Cash Flow | $35.59M | $68.82M | ($113.96M) | ($67.87M) | ($771.0K) |
| Financing Cash Flow | $77.16M | $1.59M | $97.29M | $95.63M | $10.04M |
| CapEx | $447.0K | $1.25M | $709.0K | $1.09M | $771.0K |
| Free Cash Flow | ($85.19M) | ($81.06M) | ($64.56M) | ($55.70M) | ($25.09M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.80 | 0.93 | 0.84 | 0.95 | 1.13 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -62.7% | -47.6% | -30.0% | -26.2% | -13.9% |
| Return on equity | -77.6% | -57.2% | -33.8% | -30.0% | -14.6% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 8.15 | 10.77 | 18.76 | 18.81 | 21.14 |
| Quick ratio | 8.15 | 10.77 | 18.76 | 18.81 | 21.14 |
| Cash ratio | 3.24 | 2.13 | 3.32 | 11.63 | 20.50 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.24 | 1.20 | 1.13 | 1.14 | 1.05 |
| Liabilities / Assets | 0.19 | 0.17 | 0.11 | 0.13 | 0.05 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 2.4x | 2.7x | 1.6x | 0.3x | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -17.3% | -13.1% | -41.0% | -171.5% | - |
| Net income growth (YoY) | -22.2% | -13.8% | -30.0% | -164.6% | - |
| EPS growth (YoY) | -0.6% | 9.3% | 78.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -5.1% | -25.6% | -15.9% | -122.0% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -9.9% | -32.7% | 15.5% | 28.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Aura Biosciences against the 5 most active filers in the same SIC group.